Pair Name	Resveratrol, Sorafenib
Disease Info	[ICD-11: 2C90.0]	Renal cell carcinoma		Investigative
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Down-regulation	Phosphorylation	RPS6KB1	hsa6198
	Down-regulation	Phosphorylation	RAF1	hsa5894
	Down-regulation	Phosphorylation	MEK1	hsa5604
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Expression	HIF1A	hsa3091
	Down-regulation	Expression	VEGFA	hsa7422
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	BAX	hsa581
In Vitro Model	RenCa	Mouse kidney carcinoma	Mus musculus (Mouse)	CVCL_2174
	HEK293T	Healthy	Homo sapiens (Human)	CVCL_0063
In Vivo Model	After reaching the required number of cells, the cells were harvested, washed and appropriate amount of PBS was added to prepare Renca cell suspension at a concentration of 5×10⁷ cells/mL. 0.2 mL was injected into the armpit of each mouse, and weighed and grouped the next day.
Result	PEGylated resveratrol combined with sorafenib can achieve synergistic anti-RCC activity, and the mechanism may be related to the inhibition of Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways.